Cyclopropane Carboxylic Acid

Cyclopropane Carboxylic Acid

SCHEMBL2953576

NC(=O)N1CCOCC1.O=C(O)C1CC1

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA9 Q16790 1/20 0.41
POLB P06746 1/20 0.41
HPGD P15428 1/20 0.41
PKM P14618 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
PLG P00747 1/20 0.39
PLAT P00750 1/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
HTT P42858 1/20 0.39
MMP1 P03956 1/20 0.38
MMP3 P08254 1/20 0.38
MMP8 P22894 1/20 0.38
KDM4E B2RXH2 1/20 0.38
PHGDH O43175 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL78979 0.83
SCHEMBL2952745 0.82 TSHR (0.57) TSHRSMN1; SMN2POLBHPGDPKM
SCHEMBL2952742 0.82 TSHR (0.57) TSHRSMN1; SMN2POLBHPGDPKM
Oxalic Acid SCHEMBL31346826 0.81 SMN1; SMN2 (0.48) TSHRSMN1; SMN2CA12CA1CA9
SCHEMBL487980 0.81 LMNA (0.50) TSHRSMN1; SMN2POLBPLGPLAT
Hydrochloric Acid SCHEMBL1669235 0.81 CA12 (0.52) TSHRSMN1; SMN2CA12CA1CA9
SCHEMBL27988207 0.81 CA12 (0.52) TSHRSMN1; SMN2CA12CA1CA9
Hydrochloric Acid SCHEMBL27752296 0.79 LMNA (0.48) TSHRSMN1; SMN2POLBPLGPLAT
SCHEMBL7977185 0.79 TSHR (0.58) TSHRSMN1; SMN2POLBHPGDPKM
SCHEMBL17193231 0.78 NOS2 (0.42) TSHRSMN1; SMN2POLBHPGDPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8476445-B2 Process for production of piperidine derivatives ALBANY MOLECULAR RESEARCH, INC. (US) 2013-07-02 US disclosed
US-20100137605-A1 PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES ALBANY MOLECULAR RESEARCH, INC. (US) 2010-06-03 US disclosed
US-7678915-B2 Process for production of piperidine derivatives ALBANY MOLECULAR RESEARCH, INC. (US) 2010-03-16 US disclosed
US-20070010677-A1 Process for production of piperidine derivatives AMR TECHNOLOGY, INC. (US) 2007-01-11 US disclosed
US-20050209279-A1 Process for production of piperidine derivatives AMR TECHNOLOGY, INC. (US) 2005-09-22 US disclosed
US-6919458-B2 Process for production of piperidine derivatives AMR TECHNOLOGY, INC. (US) 2005-07-19 US disclosed
EP-0868182-B1 PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES ALBANY MOLECULAR RES INC (US) 2003-09-03 EP disclosed
US-20030028029-A1 Process for production of piperidine derivatives BARCLAYS BANK PLC, AS THE COLLATERAL AGENT 2003-02-06 US disclosed
US-6458958-B1 PROCESS OF PREPARING A PIPERIDINE DERIVATIVE COMPOUND OF THE FORMULA: ACYLATING AN .ALPHA.,.ALPHA.-DISUBSTITUTED-METHYLBENZENE DERIVATIVE HAVING THE FORMULA: ALBANY MOLECULAR RESEARCH, INC. 2002-10-01 US disclosed
US-6444824-B1 ANTISEROTONINE AGENTS; SIDE EFFECT REDUCTION ALBANY MOLECULAR RESEARCH, INC. 2002-09-03 US disclosed
US-6153754-A Process for production of piperidine derivatives ALBANY MOLECULAR RESEARCH, INC. (US) 2000-11-28 US disclosed
EP-0868182-A4 PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES ALBANY MOLECULAR RES INC (US) 1999-04-07 EP disclosed
EP-0868182-A1 PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES ALBANY MOLECULAR RESEARCH, INC. (US) 1998-10-07 EP disclosed
WO-1997023213-A1 PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES ALBANY MOLECULAR RESEARCH, INC. (US) 1997-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137605-A1 PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES HPD, PTMA, HAAO TSHR 3923/4885SMN1; SMN2 2845/4885CA12 3579/4885
US-20050209279-A1 Process for production of piperidine derivatives NR5A2, NR4A1, NR4A2 TSHR 1116/4885SMN1; SMN2 3072/4885CA12 3542/4885
US-20070010677-A1 Process for production of piperidine derivatives NR4A1, NR5A2, NR4A2 TSHR 723/4885SMN1; SMN2 3353/4885CA12 3819/4885
US-20030028029-A1 Process for production of piperidine derivatives NR4A1, RCOR1, CBR1 TSHR 1779/4885SMN1; SMN2 2554/4885CA12 3957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.